Application of Stem Cell Therapy in Myelofibrosis

被引：5
|
作者：
Davidson, Marta B. [1 ]
Gupta, Vikas [2 ]
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, 700 Univ 6W091, Toronto, ON M5G 1Z5, Canada
[2] Univ Toronto, Princess Margaret Canc Ctr, Dept Med, Suite 5-303C,610 Univ Ave, Toronto, ON M5G 2M9, Canada
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2021年 / 35卷 / 02期
关键词：
Myelofibrosis; Risk-stratification; Allogeneic; Stem cell; Ruxolitinib; PROGNOSTIC SCORING SYSTEM; POST-ESSENTIAL THROMBOCYTHEMIA; AGNOGENIC MYELOID METAPLASIA; INTERNATIONAL WORKING GROUP; UMBILICAL-CORD BLOOD; MYELOPROLIFERATIVE NEOPLASMS; PREDICT SURVIVAL; MARROW-TRANSPLANTATION; POLYCYTHEMIA-VERA; DRIVER MUTATIONS;
D O I：
10.1016/j.hoc.2020.12.004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Myelofibrosis (MF) belongs to a group of clonal stem cell disorders known as the BCR-ABL-negative myeloproliferative neoplasms. Allogeneic hematopoietic stem cell transplantation (HCT) is currently the only curative treatment option for MF. Because HCT can be associated with significant morbidity and mortality, patients need to be carefully selected based on disease-risk, fitness, and transplant factors. Furthermore, in the era of JAK inhibitors, the timing of transplantation has become a challenging question. Here the authors review recent developments in HCT for MF, focusing on risk stratification and optimal timing. © 2020 The Author(s)
引用
收藏
页码：391 / 407
页数：17
相关论文
共 50 条
  • [1] Choosing between stem cell therapy and drugs in myelofibrosis
    N Kröger
    R A Mesa
    [J]. Leukemia, 2008, 22 : 474 - 486
  • [2] Choosing between stem cell therapy and drugs in myelofibrosis
    Kroeger, N.
    Mesa, R. A.
    [J]. LEUKEMIA, 2008, 22 (03) : 474 - 486
  • [3] APPLICATION OF THE MYELOFIBROSIS TRANSPLANT SCORE (MTSS) IN ALLOGENEIC STEM CELL TRASPLANTATION FOR PRIMARY AND SECONDARY MYELOFIBROSIS
    Chiusolo, P.
    Sora, F.
    Metafuni, E.
    Giammarco, S.
    Di Giovanni, A.
    Rossi, E.
    Za, T.
    Laurenti, L.
    Innocenti, I.
    Autore, F.
    De Stefano, V.
    Bacigalupo, A.
    Sica, S.
    [J]. HAEMATOLOGICA, 2019, 104 : 84 - 85
  • [4] Stem cell transplantation in myelofibrosis
    Kroeger, N.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 126 - 126
  • [5] Stem cell transplantation in myelofibrosis
    Kroeger, Nicolaus
    [J]. HEMASPHERE, 2018, 2 : 146 - 148
  • [6] Stem cell transplantation in myelofibrosis
    Kroeger, N.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 133 - 133
  • [7] Application of Stem Cell Therapy for Infertility
    Saha, Sarama
    Roy, Partha
    Corbitt, Cynthia
    Kakar, Sham S.
    [J]. CELLS, 2021, 10 (07)
  • [8] Allogeneic haematopoietic stem cell transplantation as a curative therapy in primary and secondary myelofibrosis
    Lissandre, S.
    Bay, J. -O.
    Cahn, J. -Y.
    Cacheux, V.
    Cabrespine, A.
    Cornillon, J.
    Cassinat, B.
    de Latour, R. Peffault
    Socie, G.
    Robin, M.
    [J]. BONE MARROW TRANSPLANTATION, 2009, 43 : S261 - S261
  • [9] Relapse-therapy for myelofibrosis patients after allogeneic stem cell transplantation
    Klyuchnikov, E.
    Alchalby, H.
    Badbaran, A.
    Wolschke, C.
    Ayuk, F.
    Bacher, U.
    Zander, A.
    Kroeger, N.
    [J]. BONE MARROW TRANSPLANTATION, 2010, 45 : S243 - S243
  • [10] Relapse-therapy for myelofibrosis patients after allogeneic stem cell transplantation
    Klyuchnikov, E.
    Alchalby, H.
    Badbaran, A.
    Wolschke, C.
    Ayuk, F.
    Bacher, U.
    Zander, A.
    Kroeger, N.
    [J]. ONKOLOGIE, 2010, 33 : 228 - 228
12345